Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New markets spur Martek sales

This article was originally published in The Tan Sheet

Executive Summary

DHA sales outside of infant formula products increase 40 percent during Martek Biosciences Corp.'s fiscal 2010 first quarter, which helped push the firm's revenues up 3 percent to $89.8 million. The Columbia, Md., firm March 2 said net income was roughly flat from the year-ago quarter at $9.6 million, or 29 cents per diluted share. Martek said the November-January period included $1.2 million in expenses from acquiring Amerifit Brands; excluding that expense, first-quarter earnings would have been $10.4 million, or 31 cents per diluted share, an 8 percent increase (1"The Tan Sheet" Jan. 25, 2010). CEO Steve Dubin said he is encouraged by "the prospect that we may be returning to growth in the second quarter." Martek said March 3 it extended its multi-year sole-source license and agreement to supply ARA for all of Danone's infant formula and growing-up milk products through at least 2014

You may also be interested in...



Martek Pursues Direct Consumer Access With Pending Acquisition Of Amerifit

Martek Biosciences' proposed acquisition of Amerifit Brands for $200 million would mark the omega-3 DHA ingredient supplier's first major foray into consumer marketing and would substantially expand the firm's portfolio

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

US FDA Gives Wholesalers But Not Manufacturers More Time To Begin Verifying Saleable Returns

Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel